Middle East and Africa Vaccines Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Middle East and Africa Vaccines Market Segmentation, By Composition (Combination Vaccines, and Monovaccines), Type (Subunit, Recombinant, Polysaccharide & Conjugate Vaccines, Live-Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, and DNA Vaccines), Kind (Routine Vaccine, Recommended Vaccine, and Required Vaccine), Age of Administration (Pediatric Vaccine and Adult Vaccine), Diseases (Pneumococcal Disease, Measles, Mumps & Varicella, DPT, Hepatitis, Influenza, Typhoid, Meningococcal, Rabies, Japanese Encephalitis, Yellow Fever, and Others), Route of Administration (Injectable, Oral, and Nasal), End User (Community Hospitals, Hospitals, Specialty Centres, Clinics, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2032

Middle East and Africa Vaccines Market Size

• The Middle East and Africa vaccines market size was valued at USD 1.16 billion in 2024 and is expected to reach USD 1.82 billion by 2032, at a CAGR of 5.8% during the forecast period
• The market growth is largely fueled by increasing government-led immunization programs, rising awareness about vaccine-preventable diseases, and the prevalence of infectious diseases such as influenza, hepatitis, and pneumococcal infections
• Furthermore, international initiatives such as Gavi’s funding and support for vaccine access in the region, along with rising consumer demand for safe and effective vaccines, are establishing vaccination as a critical public health priority. These converging factors are accelerating the uptake of vaccines, thereby significantly boosting the industry’s growth

Middle East and Africa Vaccines Market Analysis

• Vaccines, providing immunization against infectious diseases, are increasingly vital components of public health strategies in both human and animal populations across the Middle East and Africa due to their ability to prevent outbreaks, reduce disease burden, and improve overall population health
• The escalating demand for vaccines is primarily fueled by government-led immunization programs, rising awareness of vaccine-preventable diseases, and increasing prevalence of infectious diseases such as influenza, hepatitis, and pneumococcal infections
• Saudi Arabia dominated the Middle East and Africa vaccines market with the largest revenue share of 28.5% in 2024, characterized by robust healthcare infrastructure, strong vaccination campaigns, and substantial government support, with significant growth in pediatric and adult immunization programs driven by both local health authorities and international partnerships such as Gavi
• South Africa is expected to be the fastest growing country in the Middle East and Africa vaccines market during the forecast period due to increasing healthcare investments, rising awareness, and expanding vaccination outreach programs
• Combination vaccines segment dominated the Middle East and Africa vaccines market with a market share of 37.6% in 2024, driven by their ability to provide protection against multiple diseases in a single dose, improving compliance and reducing healthcare costs

Report Scope and Middle East and Africa Vaccines Market Segmentation   

Middle East and Africa Vaccines Market Trends

Expansion of Vaccine Access Through Digital Health and Mobile Platforms

• A significant and accelerating trend in the MEA vaccines market is the integration of digital health platforms and mobile technology to enhance vaccine accessibility, track immunization schedules, and improve coverage in remote and underserved areas

  • For instance, mobile applications in Saudi Arabia allow caregivers to receive vaccine reminders, schedule appointments, and access immunization records electronically, streamlining the vaccination process

• Digital platforms also enable health authorities to monitor vaccine stock levels, predict demand, and optimize distribution logistics, reducing wastage and ensuring timely availability of vaccines across urban and rural regions
• In addition, integration with broader health information systems facilitates centralized management of vaccination campaigns, enabling authorities to coordinate outreach efforts, report adverse events, and analyze immunization data more effectively
• This trend towards digital and connected vaccine delivery systems is reshaping public health strategies, with companies and government initiatives increasingly deploying mobile-enabled vaccination tracking solutions to improve coverage and efficiency
• The demand for vaccine programs that leverage digital health technologies is growing rapidly across both human and animal vaccination initiatives, as stakeholders prioritize accessibility, efficiency, and data-driven immunization planning

Middle East and Africa Vaccines Market Dynamics

Driver

Increasing Government Immunization Programs and Disease Awareness

• The rising prevalence of infectious diseases and proactive government immunization initiatives across the MEA region are significant drivers for heightened vaccine demand

  • For instance, Saudi Arabia’s national immunization program actively promotes routine childhood and adult vaccinations, increasing public awareness and uptake of recommended vaccines

• As communities become more aware of preventable diseases such as influenza, hepatitis, and pneumococcal infections, demand for vaccines offering effective protection continues to grow steadily
• Furthermore, international support programs, such as Gavi, provide funding and vaccine access, enhancing government capabilities to expand immunization coverage across the region
• Public campaigns emphasizing vaccine safety, effectiveness, and community protection also contribute to increasing acceptance and adoption among populations in both urban and rural areas
• The combined effect of awareness, policy initiatives, and international support is accelerating vaccine uptake, making immunization a cornerstone of public health strategies across MEA countries

Restraint/Challenge

Logistical Constraints and Vaccine Hesitancy

• Challenges such as limited cold chain infrastructure, supply chain inefficiencies, and storage requirements pose significant hurdles for widespread vaccine distribution in the MEA region

  • For instance, remote areas in countries such as Nigeria and Sudan face difficulties in maintaining consistent refrigeration for vaccines, potentially compromising potency and coverage

• Vaccine hesitancy and misinformation among certain populations further restrict uptake, with concerns over side effects and mistrust of immunization programs impacting overall adoption rates
• Addressing these challenges through investment in cold chain logistics, training healthcare workers, and community engagement initiatives is essential to improve vaccine reach and public confidence
• In addition, high costs of certain vaccines and limited access to advanced combination vaccines can act as barriers, especially for low-income communities, necessitating subsidies and government support
• Overcoming logistical, educational, and cost-related obstacles is vital for sustaining growth in the MEA vaccines market and ensuring broad immunization coverage across diverse populations

Middle East and Africa Vaccines Market Scope

The market is segmented on the basis of composition, type, kind, age of administration, diseases, route of administration, end user, and distribution channel.

• By Composition

On the basis of composition, the Middle East and Africa vaccines market is segmented into combination vaccines and monovaccines. The combination vaccines segment dominated the market with the largest revenue share of 37.6% in 2024. These vaccines provide immunization against multiple diseases in a single dose, reducing the number of injections required and improving patient compliance. Governments and healthcare providers prefer combination vaccines as they simplify immunization schedules and reduce logistical burdens. Parents favor them to minimize hospital visits and discomfort for children. Major countries such as Saudi Arabia, South Africa, and Egypt include combination vaccines in their national immunization programs. Continuous product innovation and expanded disease coverage further strengthen their market position.

The monovaccines segment is expected to witness the fastest growth from 2025 to 2032 due to rising demand for targeted immunization programs against specific diseases such as influenza, rabies, and typhoid. Monovaccines are critical in outbreak situations where rapid, focused vaccination is required. Awareness among healthcare providers and communities about disease-specific prevention is increasing. New regional manufacturers are introducing cost-effective monovaccine options to improve accessibility. Monovaccines allow flexible scheduling and tailored immunization plans for high-risk groups. Adoption is also supported by private clinics and travel vaccination programs targeting adults.

• By Type

On the basis of type, the Middle East and Africa vaccines market is segmented into subunit, recombinant, polysaccharide & conjugate vaccines, live-attenuated, inactivated, toxoid, and DNA vaccines. The polysaccharide & conjugate vaccines segment dominated in 2024 due to effectiveness against bacterial infections such as pneumococcal and meningococcal diseases. These vaccines are widely used in pediatric immunization programs across Saudi Arabia, South Africa, and Egypt. Government initiatives support preventive immunization to reduce invasive bacterial infections. Public awareness campaigns emphasize protection against severe diseases. Healthcare providers prefer these vaccines for infants and children due to proven efficacy. Ongoing introduction of combination polysaccharide-conjugate vaccines further enhances compliance and convenience.

The recombinant vaccines segment is expected to witness the fastest growth during forecast period due to rising research and development of genetically engineered vaccines for hepatitis B and emerging viral infections. Recombinant vaccines are valued for safety, scalability, and efficacy in both pediatric and adult populations. International funding and partnerships support the introduction of novel recombinant vaccines. Increased awareness of viral disease prevention among healthcare providers and populations is driving adoption. Recombinant vaccines are increasingly included in private healthcare offerings and national programs. Technological advancements are also making production faster and more cost-effective.

• By Kind

On the basis of kind, the Middle East and Africa vaccines market is segmented into routine, recommended, and required vaccines. The routine vaccines segment dominated the market with the largest revenue share in 2024 due to established national immunization schedules. Routine vaccines such as DPT, polio, and measles are universally administered to children in Saudi Arabia, South Africa, and Egypt. Government funding and awareness campaigns ensure high coverage rates. Routine vaccines are prioritized in urban and rural healthcare infrastructure. Parents and caregivers follow standard schedules for children, contributing to consistent demand. Supply chain prioritization ensures availability in hospitals and clinics across the region.

The recommended vaccines segment is expected to witness the fastest growth from 2025 to 2032 due to increasing awareness about additional protection against diseases such as influenza, typhoid, and HPV. Recommended vaccines are often adopted by adults and high-risk populations. Private healthcare providers are expanding preventive health offerings, including these vaccines. Awareness campaigns, physician recommendations, and rising disposable incomes in GCC countries are supporting adoption. Recommended vaccines are increasingly available in retail and online pharmacies. Government initiatives also encourage uptake among travelers and vulnerable groups.

• By Age of Administration

On the basis of age, the Middle East and Africa vaccines market is segmented into pediatric and adult vaccines. The pediatric vaccine segment dominated the market in 2024 due to strong government focus on child immunization. Pediatric vaccines form the core of routine schedules in Saudi Arabia, Egypt, and South Africa. National programs and school-based campaigns ensure high coverage. Caregivers prioritize timely vaccination for children to prevent serious diseases. Pediatric combination vaccines reduce the number of injections, improving compliance. Organizations such as Gavi reinforce pediatric vaccine availability through funding and distribution programs.

The adult vaccine segment is expected to witness the fastest growth during forecast period due to rising awareness of influenza, hepatitis, and travel-related vaccines. Urban adults and high-risk groups increasingly seek preventive care. Employers and private healthcare providers are promoting adult vaccination as part of workplace health programs. Vaccination campaigns targeting elderly populations support segment growth. Mobile reminders and community outreach enhance accessibility. Increasing disposable incomes enable broader adoption of recommended vaccines among adults.

• By Diseases

On the basis of diseases, the Middle East and Africa vaccines market is segmented into pneumococcal, measles/mumps/varicella, DPT, hepatitis, influenza, typhoid, meningococcal, rabies, Japanese encephalitis, yellow fever, and others. The pneumococcal disease segment dominated in 2024 due to high prevalence in children and the elderly. National immunization programs in Saudi Arabia, South Africa, and Egypt prioritize pneumococcal vaccines. Conjugate vaccines provide strong immune response and long-term protection. Public awareness campaigns highlight the severity of bacterial infections. International support ensures adequate supply and accessibility. Hospitals and clinics actively administer these vaccines across urban and rural areas.

The influenza segment is expected to witness the fastest growth during forecast period due to seasonal outbreaks and rising adult immunization awareness. Governments recommend annual influenza vaccination for high-risk groups. Urban populations and healthcare workers are primary targets. Quadrivalent influenza vaccines enhance protection and adoption. Awareness campaigns emphasize prevention of seasonal morbidity and mortality. Private healthcare and employer programs drive uptake among adults.

• By Route of Administration

On the basis of route, the Middle East and Africa vaccines market is segmented into injectable, oral, and nasal vaccines. The injectable segment dominated in 2024 due to established delivery methods and higher efficacy. Hospitals and clinics widely administer injectable vaccines for both pediatric and adult populations. Precise dosing ensures long-lasting immunity. Inclusion in national programs strengthens coverage. Public campaigns promote injectable vaccines as safe and effective. Healthcare providers rely on injectable vaccines for immunization consistency.

The oral segment is expected to witness the fastest growth during forecast period due to ease of administration for mass campaigns against polio and rotavirus. Oral vaccines reduce the need for trained personnel in rural areas. Acceptance among children and caregivers is higher due to needle-free delivery. Government campaigns in Nigeria, Egypt, and South Africa support growth. Oral vaccines are ideal for rapid deployment during outbreaks. International organizations assist in distribution and awareness.

• By End User

On the basis of end user, the Middle East and Africa vaccines market is segmented into community hospitals, hospitals, specialty centers, clinics, and others. The hospitals segment dominated in 2024 due to centralized immunization programs and cold chain infrastructure. Hospitals provide vaccination services for both children and adults. National campaigns utilize hospitals as primary vaccination points. Hospitals serve as distribution hubs for smaller clinics and specialty centers. Patient health records integration supports follow-up and monitoring. Hospitals ensure proper administration and storage of vaccines.

The clinics segment is expected to witness the fastest growth during forecast period due to increasing private healthcare access and convenience. Clinics provide flexible schedules and personalized care for routine and recommended vaccines. Urban population expansion drives clinic-based adoption. Private clinics are offering combination and adult vaccines. Community and mobile clinics improve outreach in semi-urban and rural areas. Awareness campaigns by clinics encourage preventive health adoption.

• By Distribution Channel

On the basis of distribution channel, the Middle East and Africa vaccines market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated in 2024 due to direct access to patients during hospital visits. Hospitals ensure proper cold chain management and trained staff for vaccine administration. Inclusion in immunization programs strengthens the channel. Hospitals coordinate bulk procurement for consistent supply. Patients trust hospital-administered vaccines for safety and efficacy. Government-supported programs reinforce hospital pharmacy dominance.

The online pharmacy segment is expected to witness the fastest growth during forecast period, due to rising digital adoption and e-commerce platforms. Online channels provide home delivery, reminders, and easy reordering. Urban populations and tech-savvy consumers drive demand. Regulatory approvals and logistics partnerships ensure safe distribution. Convenience and accessibility encourage uptake among adults and caregivers. Digital health integration supports broader vaccine awareness and adherence.

Middle East and Africa Vaccines Market Regional Analysis

• Saudi Arabia dominated the Middle East and Africa vaccines market with the largest revenue share of 28.5% in 2024, characterized by robust healthcare infrastructure, strong vaccination campaigns, and substantial government support, with significant growth in pediatric and adult immunization programs driven by both local health authorities and international partnerships such as Gavi
• Consumers in the region increasingly prioritize the protection offered by vaccines against diseases such as pneumococcal infections, influenza, and hepatitis, recognizing the importance of immunization for both children and adults
• This widespread adoption is further supported by robust healthcare infrastructure, active participation in international initiatives such as Gavi, and growing investments in cold chain logistics, establishing vaccines as a critical component of public health strategy across both urban and rural areas

The Saudi Arabia Vaccines Market Insight

The Saudi Arabia vaccines market captured the largest revenue share of 28.5% in 2024 within the MEA region, fueled by strong government immunization programs and high healthcare expenditure. Consumers are increasingly prioritizing protection against vaccine-preventable diseases such as pneumococcal infections, influenza, and hepatitis. The country’s focus on pediatric and adult immunization programs, combined with active participation in international initiatives such as Gavi, further propels market growth. In addition, the availability of advanced vaccines and combination formulations is driving adoption. The robust healthcare infrastructure and widespread awareness campaigns ensure consistent coverage across urban and rural populations.

South Africa Vaccines Market Insight

The South Africa vaccines market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by rising awareness of infectious diseases and government-led vaccination initiatives. Increasing urbanization, coupled with growing accessibility to healthcare facilities, is fostering vaccine adoption. Consumers are drawn to the protection offered by vaccines for both children and adults. Public health campaigns emphasizing immunization benefits further support market growth. The country is witnessing significant uptake across hospitals, clinics, and community health centers, ensuring comprehensive immunization coverage.

Egypt Vaccines Market Insight

The Egypt vaccines market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by expanding national immunization programs and the government’s efforts to improve healthcare access. Concerns regarding preventable diseases encourage widespread acceptance among caregivers and adults. Egypt’s investments in cold chain infrastructure and healthcare delivery systems are expected to stimulate market growth. The inclusion of combination vaccines in routine schedules enhances convenience and compliance. Private and public healthcare sectors actively support immunization drives, ensuring strong demand. Awareness campaigns by the Ministry of Health and NGOs further boost vaccine adoption.

Nigeria Vaccines Market Insight

The Nigeria vaccines market is expected to expand at a considerable CAGR during the forecast period, fueled by rising disease prevalence, government vaccination campaigns, and international support from organizations such as Gavi. Public awareness initiatives and school-based immunization programs are increasing coverage among children. Nigeria’s improving healthcare infrastructure facilitates vaccine distribution and accessibility. Community outreach programs are helping overcome logistical challenges in rural areas. The adoption of combination vaccines is enhancing compliance and efficiency. Increasing donor funding and partnerships strengthen vaccine availability and market growth.

Middle East and Africa Vaccines Market Share

The Middle East and Africa Vaccines industry is primarily led by well-established companies, including:

• Vaccine Industrial Holding LLC (Saudi Arabia)
• VBC (Egypt)
• Hayat Biotech (U.A.E.)
• Arabio (U.A.E.)
• biovac.co.za. (South Africa)
• GSK plc (U.K.)
• AstraZeneca (U.K.)
• Moderna, Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Johnson & Johnson and its afiliates (U.S.)
• SINOVAC (China)
• China National Pharmaceutical Group Co Ltd. (China) Bavarian Nordic (Denmark)
• BioNTech (Germany)
• Hikma Pharmaceuticals PLC (Jordan)
• NewBridge Pharmaceuticals (U.A.E.)
• EmendoBio (Israel)
• Protalix BioTherapeutics Inc. (Israel)
• Vaccine Valley (U.A.E.)
• The Veterinary Group (U.A.E.)

What are the Recent Developments in Middle East and Africa Vaccines Market?

• In August 2025, health leaders and partners pledged to accelerate Africa's production of medicines and vaccines during the Seventy-fifth session of the WHO Regional Committee for Africa in Lusaka. This commitment underscores the continent's dedication to enhancing local manufacturing capabilities and ensuring equitable access to vaccines
• In February 2025, Uganda launched a clinical trial for a vaccine targeting the Sudan strain of Ebola, developed by the International AIDS Vaccine Initiative. This trial, conducted by the Makerere Lung Institute, involves approximately 2,460 doses and aims to address the gap in vaccine availability for this particular strain
• In December 2023, BioNTech inaugurated a commercial-scale mRNA vaccine manufacturing facility in Kigali, Rwanda. This facility aims to bolster Africa's capacity to produce vaccines locally, reducing dependency on external sources and enhancing self-sufficiency in combating infectious diseases
• In October 2023, the Africa Centres for Disease Control and Prevention (Africa CDC) and Gavi hosted the First Manufacturers Marketplace for Vaccine Manufacturing in Marrakech, Morocco. This event aimed to strengthen vaccine production capabilities within African Union member states, fostering collaboration and innovation in vaccine manufacturing
• In September 2023, Cameroon became the first country to regularly administer the RTS,S/AS01 malaria vaccine to children. Supported by Gavi, WHO, and UNICEF, this initiative aims to vaccinate approximately 250,000 children by the end of 2024, marking a significant step in malaria control efforts in Africa

SKU-59879